Last reviewed · How we verify
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma
CLIC-YYC-GPNMB-01 is a Single Patient Study (SPS) developed according to the Health Canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there are no options of treatment or cure remaining. The patient under consideration for CLIC-YYC-GPNMB-01 has progressive metastatic alveolar soft part sarcoma (ASPS). The investigators propose to treat the patient with GCAR1, a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
Details
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | COMPLETED |
| Enrolment | 1 |
| Start date | Wed Sep 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Sep 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Alveolar Soft Part Sarcoma
Interventions
- GCAR1
Countries
Canada